The National Institute of Health is Investing in COVID-19 Testing Technologies to Meet U.S. Demand
The National Institute of Health (NIH) is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing. NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase the number, type and availability of tests by millions per week as early as September 2020.
With national demand estimated to be millions more tests per day above current levels, these technologies are expected to make a significant contribution to expanding the nation’s testing capacity.
The Secretary of the Department of Health and Human Services has recognised, “RADx moved incredibly quickly to select promising technologies through its ‘shark tank’ approach, investing in technologies that could boost America’s best-in-the-world COVID-19 testing capacity by millions more tests per day. These technologies will help deliver faster results from labs and more and more test results within minutes at the point of care, which is especially important for settings like schools and nursing homes.”
This is an exciting milestone to attempt to guide patient care and inform public health measures to stop the spread of the virus, as well as leave the U.S. better equipped to address future viruses and diseases.
